Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02249429 · ClinicalTrials.gov registry record · Phase 2
Open-Label, Non Randomized Phase 2 Study With Safety Run-In
A Phase 2 study of Lymphoma, Malignant, sponsored by PIQUR Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 53
- Enrollment target
- 12
- Study locations
NCT02249429: Completed Phase 2 study of Lymphoma, Malignant, sponsored by PIQUR Therapeutics.
NCT02249429 is a Phase 2 study of Lymphoma, Malignant that has completed, run by PIQUR Therapeutics. The registered enrollment target is 53 participants. The trial reports 12 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02249429, a Phase 2 study of Lymphoma, Malignant, has completed, sponsored by PIQUR Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 53 participants
- Enrollment target
- 12
- Study locations
Study Summary
The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or refractory lymphomas.
Conditions Studied
Interventions
- DRUG bimiralisib
Study Locations (12)
Other
- University Clinical Center Republic of Srpska - Banja Luka
- University Clinical Center Sarajevo - Sarajevo
- Univeristy Hospital Haifa - Haifa
- Institute for Oncology and radiology of Serbia - Belgrade
- Clinical Center Kragujevac - Kragujevac
- Clinical Center Nis - Niš
- Guy's Hospital - London
- Royal Marsden NHS Foundation Trust - London
- University College Hospital London - London
- Churchill Hospital - Oxford
New York
- Weill Cornell Medicine - New York
Paris
- Insitute Curie - Saint-Cloud
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02249429
The ClinicalTrials.gov registry entry for NCT02249429 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PIQUR Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lymphoma, Malignant appearing as the primary indexed condition, and to 1 intervention - of which bimiralisib is the first listed.
NCT02249429 reports 12 study locations spanning 3 distinct geographic areas - top geographies include Other, New York, Paris.
Frequently Asked Questions
What is clinical trial NCT02249429 about?
NCT02249429 is a clinical study titled "Open-Label, Non Randomized Phase 2 Study With Safety Run-In". The main goal of this study is to determine the Maximum Tolerated Dose (MTD) and the Recommended Phase II Dose (RP2D) as well as preliminary antitumor activity of bimiralisib (PQR309) administered orally, as once daily capsules continuously and on intermittent schedule in patients with relapsed or r...
What is the current status of trial NCT02249429?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2015-05. Estimated completion is 2018-09-11.
What conditions does trial NCT02249429 study?
This clinical trial studies the following conditions: Lymphoma, Malignant.
What interventions are being tested in trial NCT02249429?
The interventions under investigation include: bimiralisib (DRUG).
Who is sponsoring clinical trial NCT02249429?
This trial is sponsored by PIQUR Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02249429 being conducted?
This trial has 12 study locations across New York, Paris. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma, Malignant
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.